Phase III APACT Trial: Adjuvant nab-Paclitaxel Plus Gemcitabine vs Gemcitabine in Patients With Surgically Resected Pancreatic Adenocarcinoma

May 31 - June 4, 2019; Chicago, Illinois
In the phase III APACT trial, adding nab-paclitaxel to adjuvant gemcitabine did not significantly prolong DFS by independent review but improved OS in an interim analysis in resected pancreatic cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 182 KB
Released: June 4, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Blueprint Medicines
Celgene Corporation
Taiho Oncology Inc.

Related Content

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastrointestinal cancer

Allison M. Cushman-Vokoun, MD, PhD John L. Marshall, MD Released: August 5, 2021

Gain clinical insights quickly with this short slideset from Clinical Care Options (CCO) on key actionable biomarkers for GI cancers

David H. Ilson, MD, PhD John L. Marshall, MD Eric Van Cutsem, MD, PhD Released: July 23, 2021

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and gastroesophageal cancers

David H. Ilson, MD, PhD Released: July 15, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue